Showing results (21-30 of 396) with videos related to
Sort By:
Pageof 40
Biochemical Pharmacology|April 13, 2010
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinomaKeith T Flaherty, Igor PuzanovSeminars in Cutaneous Medicine and Surgery|November 6, 2010
Targeted molecular therapy in melanomaIgor Puzanov, Keith T FlahertyCancer|July 15, 2010
BRAF, a target in melanoma: implications for solid tumor drug developmentKeith T Flaherty, Grant McArthurThe British Journal of Dermatology|June 26, 2025
The Rise of New Targets in MelanomaXue Bai, Keith T FlahertyNature Clinical Practice. Oncology|December 19, 2008
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?Keith T Flaherty, Weijing SunCurrent Opinion in Oncology|February 10, 2012
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insightsReinhard Dummer, Keith T FlahertyExpert Reviews in Molecular Medicine|October 13, 2012
MEK and RAF inhibitors for BRAF-mutated cancersSarah Belden, Keith T FlahertyAnnals of Internal Medicine|August 4, 2018
When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of AgeShiuh-Wen Luoh, Keith T FlahertyClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2012
BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistanceAlexander Marzuka Alcalá, Keith T FlahertyTrends in Cancer|July 26, 2017
Biomarkers in Melanoma: Lessons from Translational MedicineElizabeth I Buchbinder, Keith T FlahertyPageof 40